DAS is a narrow therapeutic index drug and a novel tyrosine kinase multitarget inhibitor of the BCR-ABL and Src family of kinases was permitted for the treatment of chronic myelogenous leukemia (CML) by the US FDA, as well as for Ph+ ALL patients who could not tolerate first-line therapy [5,6]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.